Abstract:Background: Chronic obstructive pulmonary disease (COPD) is characterized by persistent respiratory symptoms and airflow limitation due to airway and/or alveolar remodeling. Although the abnormalities are primarily prompted by chronic exposure to inhaled irritants, maladjusted and self-reinforcing immune responses are significant contributors to the development and progression of the disease. The p38 isoforms are regarded as pivotal hub proteins that regulate immune and inflammatory responses in both healthy and disease states. As a result, their inhibition has been the subject of numerous recent studies exploring their therapeutic potential in COPD. Main body: We performed a systematic search based on the PRISMA guidelines to find relevant studies about P38 signaling in COPD patients. We searched the PubMed and Google Scholar databases and used "P38" AND "COPD" Mesh Terms. We applied the following inclusion criteria: (1) human, animal, ex vivo and in vitro studies; (2) original research articles; (3) published in English; and (4) focused on P38 signaling in COPD pathogenesis, progression, or treatment. We screened the titles and abstracts of the retrieved studies and assessed the full texts of the eligible studies for quality and relevance. We extracted the following data from each study: authors, year, country, sample size, study design, cell type, intervention, outcome, and main findings. We classified the studies according to the role of different cells and treatments in P38 signaling in COPD. Conclusion: While targeting p38 MAPK has demonstrated some therapeutic potential in COPD, its efficacy is limited. Nevertheless, combining p38 MAPK inhibitors with other anti-inflammatory steroids appears to be a promising treatment choice. Clinical trials testing various p38 MAPK inhibitors have produced mixed results, with some showing improvement in lung function and reduction in exacerbations in COPD patients. Despite these mixed results, research on p38 MAPK inhibitors is still a major area of study to develop new and more effective therapies for COPD. As our understanding of COPD evolves, we may gain a better understanding of how to utilize p38 MAPK inhibitors to treat this disease. Video Abstract.

Progression of the PI3K/Akt signaling pathway in chronic obstructive pulmonary disease

Advances in the Discovery of Novel Inhaled PI3K Inhibitors for the Treatment of Asthma

p38 MAPK signaling in chronic obstructive pulmonary disease pathogenesis and inhibitor therapeutics

Molecular Pathogenesis in Chronic Obstructive Pulmonary Disease and Therapeutic Potential by Targeting AMP‐activated Protein Kinase

Molecular pathogenesis in chronic obstructive pulmonary disease and therapeutic potential by targeting AMP-activated protein kinase: AMPK in chronic obstructive pulmonary disease

Mitochondrial Alterations During Oxidative Stress In Chronic Obstructive Pulmonary Disease

WNT/β-catenin Signaling Regulates Cigarette Smoke-Induced Airway Inflammation Via the PPARδ/p38 Pathway

Research progress of PI3K/Akt/mTOR signal pathway on hypoxic pulmonary hypertension

Perspectives on Wnt Signal Pathway in the Pathogenesis and Therapeutics of Chronic Obstructive Pulmonary Disease.

Current Concepts on Oxidative/carbonyl Stress, Inflammation and Epigenetics in Pathogenesis of Chronic Obstructive Pulmonary Disease

Activation of Hypoxia-Inducible Factor-1 Alpha Via Nuclear Factor-Kappa B in Rats with Chronic Obstructive Pulmonary Disease

Potential Natural Small Molecular Compounds for the Treatment of Chronic Obstructive Pulmonary Disease: An Overview

CHF6523 data suggest that the phosphoinositide 3-kinase delta isoform is not a suitable target for the management of COPD

Exploring Molecular Mechanisms and Biomarkers in COPD: An Overview of Current Advancements and Perspectives

Targeting PI3K/AKT Signaling for Treatment of Idiopathic Pulmonary Fibrosis

Pathogenesis of chronic obstructive pulmonary disease (COPD) induced by cigarette smoke

Integrating 3-omics data analyze rat lung tissue of COPD states and medical intervention by delineation of molecular and pathway alterations

Cellular and Molecular Biology of Mitochondria in Chronic Obstructive Pulmonary Disease

Particulate matter in COPD pathogenesis: an overview

Exploration of Multi-Aspect Development of Chronic Obstructive Pulmonary Disease Pathogenesis, Diagnosis, and Treatment Management

The Role of Lysophospholipid Metabolites LPC and LPA in the Pathogenesis of Chronic Obstructive Pulmonary Disease